OpenAlex
PricingAboutJobs
Log inGet started
Work

The anti-CD20 antibody rituximab reduces the Th17 cell response

HTML

Year: 2011
Type: article
Study design: Clinical Trial
Source: Arthritis & Rheumatism
DOI: 10.1002/art.30314
Authors: Frank L. van de Veerdonk, Bernard Lauwerys, Renoud J. Marijnissen, Kim Timmermans, Franco Di Padova, Marije I. Koenders, Ilse Gutierrez-Roelens, Patrick Durez, Mihai G. Netea, Jos W. M. van der Meer, Wim B. van den Berg, Leo A. B. Joosten
Institutions: Radboud University Nijmegen, Radboud University Medical Center, UCLouvain, Novartis Institutes for BioMedical Research
Language: English

Topic: Rheumatoid Arthritis Research and Therapies
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Keywords: rituximab, rheumatoid arthritis, Th17 cells, B cells, anti-CD20 monoclonal antibody, RORγt, IL-22, IL-17, Candida albicans, synovitis, X-linked agammaglobulinemia, B-cell depletion, autoimmune disease therapy
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2046188285
FWCI: 15.81
Cites: 34
Cited by: 193
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms